Heat‐precipitation allows the efficient purification of a functional plant‐derived malaria transmission‐blocking vaccine candidate fusion protein
- 23 January 2015
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (7) , 1297-1305
Abstract
Malaria is a vector‐borne disease affecting more than two million people and accounting for more than 600,000 deaths each year, especially in developing countries. The most serious form of malaria is caused by Plasmodium falciparum. The complex life cycle of this parasite, involving pre‐erythrocytic, asexual and sexual stages, makes vaccine development cumbersome but also offers a broad spectrum of vaccine candidates targeting exactly those stages. Vaccines targeting the sexual stage of P. falciparum are called transmission‐blocking vaccines (TBVs). They do not confer protection for the vaccinated individual but aim to reduce or prevent the transmission of the parasite within a population and are therefore regarded as an essential tool in the fight against the disease. Malaria predominantly affects large populations in developing countries, so TBVs need to be produced in large quantities at low cost. Combining the advantages of eukaryotic expression with a virtually unlimited upscaling potential and a good product safety profile, plant‐based expression systems represent a suitable alternative for the production of TBVs. We report here the high level (300 μg/g fresh leaf weight (FLW)) transient expression in Nicotiana benthamiana leaves of an effective TBV candidate based on a fusion protein F0 comprising Pfs25 and the C0‐domain of Pfs230, and the implementation of a simple and cost‐effective heat treatment step for purification that yields intact recombinant protein at >90% purity with a recovery rate of >70%. The immunization of mice clearly showed that antibodies raised against plant‐derived F0 completely blocked the formation of oocysts in a malaria transmission‐blocking assay (TBA) making F0 an interesting TBV candidate or a component of a multi‐stage malaria vaccine cocktail. Biotechnol. Bioeng. 2015;112: 1297–1305.Keywords
Funding Information
- Fraunhofer-Gesellschaft
This publication has 45 references indexed in Scilit:
- Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbitsPlant Biotechnology Journal, 2014
- Rational design of a host cell protein heat precipitation step simplifies the subsequent purification of recombinant proteins from tobaccoBiochemical Engineering Journal, 2014
- Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic BackgroundsInfection and Immunity, 2013
- The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in TanzaniaPLOS ONE, 2010
- A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adultsParasite Immunology, 2007
- Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.Journal of Experimental Medicine, 1991
- Plasmodium falciparum: An abundant stage-specific protein expressed during early gametocyte developmentExperimental Parasitology, 1989
- Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies.Journal of Experimental Medicine, 1989
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Experiments upon the feeding of Aëdes aegypti through animal membranes with a view to applying this method to the chemotherapy of malariaParasitology, 1946